Turn Therapeutics remains a high-risk, pre-commercial entity characterized by a total absence of revenue and a cost structure heavily skewed toward $2.1M in quarterly SG&A expenses. The company's recent pivot toward debt financing, evidenced by a debt-to-equit...
Price trend, volume and key moving averages
Trailing total returns as of 9/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.20-900.0% vs -$0.02 | — vs — |
Q2 2026 May 11, 2026 | -$0.03-50.0% vs -$0.02 | — vs — |
Q2 2026 Mar 31, 2026 | $0.01+118.6% vs -$0.05 | — vs — |
Q4 2025 Nov 13, 2025 | -$0.07-37.3% vs -$0.05 | — vs — |
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, toda
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease. The study, published in Life, showed that pretreatment with GX-.
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and six months ended June 30, 2026. “The second quarter was one of the most productive periods in Turn Therapeutics' history. Our review of interim GX-03 Phase 2 data showed activity across a broader range of.
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today
Benchmark TTRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Turn Therapeutics Inc. (TTRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.66 | $377.12M | -55.04 | — | — | -141.67% | — | |
| $29.06 | $3.65B | -8.83 | -4.26% | -386.32% | -87.98% | — | |
| $39.57 | $8.17B | -14.29 | — | -7585.86% | -69.59% | — | |
| $24.39 | $3.05B | -187.62 | 91.34% | 6.15% | 15.05% | — | |
| $116.47 | $9.58B | -31.56 | -16.72% | -285.41% | -21.5% | — | |
| $352.48 | $9.83B | -26.15 | -100% | — | -34.15% | — |
Turn Therapeutics Inc. (TTRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TTRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Turn Therapeutics Inc. (TTRX) stock FAQ — growth, dividends, profitability & financials explained
Turn Therapeutics Inc. (TTRX) reported a net loss of $8.4M for fiscal year 2025.
Turn Therapeutics Inc. (TTRX) has a return on equity (ROE) of -141.7%. Negative ROE indicates the company is unprofitable.
Turn Therapeutics Inc. (TTRX) had negative free cash flow of $4.3M in fiscal year 2025, likely due to heavy capital investments.
